Clinical Trial Update: Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes [Phase 2]

View source ↗

Summary

Phase 2 trial of rivoglitazone in type 2 diabetes completed; the study evaluated placebo and an active comparator to characterize dose–response relationships.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Rivoglitazone (rivoglitazone)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Type 2 Diabetes | Phase 2 | Status: COMPLETED